Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zaina Al-Mohtaseb

Ophthalmology Houston, TX Medical Doctor

NPI 1659506822 CMS profile 302285

6565 Fannin St # Nc205, Houston, TX 77030

Open in the dashboard

General payments

$636,074

622 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$447,817 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Zaina Al-Mohtaseb of Houston, TX is reported in the CMS Open Payments database as having received $636,074 across 622 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $447,817 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $162,111 136
2024 General $189,958 132
2023 General $71,017 108
2022 General $77,209 84
2021 General $32,194 49
2020 General $39,489 27
2019 General $64,095 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zaina Al-Mohtaseb
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Zaina Al-Mohtaseb were reported at $162,111. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Zaina Al-Mohtaseb Ophthalmology median Middle half National median
2019 $64,095 $258 $104–$655 $163
2020 $39,489 $126 $45–$321 $114
2021 $32,194 $205 $76–$534 $132
2022 $77,209 $266 $100–$678 $149
2023 $71,017 $308 $117–$745 $160
2024 $189,958 $340 $127–$846 $164
2025 $162,111 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tarsus Pharmaceuticals, Inc. $167,657 91 payments
  2. Alcon Vision LLC $123,787 146 payments
  3. Johnson & Johnson Surgical Vision, Inc. $67,622 45 payments
  4. Bausch & Lomb Americas Inc. $46,468 52 payments
  5. Carl Zeiss Meditec, Inc. $42,839 37 payments
  6. Alcon Research LLC $41,618 23 payments
  7. Allergan Inc. $24,132 25 payments
  8. Beaver-Visitec International, Inc. $24,000 13 payments
  9. Bausch & Lomb, a division of Bausch Health US, LLC $19,009 20 payments
  10. Glaukos Corporation $16,470 42 payments
  11. Other $62,471 128 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $360,717 170 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $185,570 32 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $28,350 9 payments
  4. Travel and Lodging $22,038 86 payments
  5. Food and Beverage $18,934 312 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $9,500 4 payments
  7. Long term medical supply or device loan $7,615 3 payments
  8. Honoraria $3,278 4 payments
  9. Education $55 1 payment
  10. Gift $17 1 payment
Products named General payments · program years 2019–2025
  1. XDEMVY $155,707 83 payments
  2. Tecnis Simplicity $60,525 22 payments
  3. STAR S4 IR $60,053 19 payments
  4. Tecnis IOL $60,053 19 payments
  5. Centurion $43,242 31 payments
  6. Clareon $38,206 28 payments
  7. MIEBO $26,219 25 payments
  8. XIIDRA $24,468 23 payments
  9. AcrySof IQ PanOptix UV IOL $20,740 17 payments
  10. VERACITY SURGICAL $17,475 12 payments
  11. Other $296,432 408 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

384

Median for Ophthalmology: 891

Drug cost

$40,283

Median for Ophthalmology: $68,233

Branded share of claims

54.9%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lotemax Sm Loteprednol Etabonate Brand 55 $13,704
Miebo Perfluorohexyloctane/Pf Brand 18 $12,644
Prednisolone Acetate Generic 119 $7,278
Loteprednol Etabonate Generic 29 $4,079
Moxifloxacin Moxifloxacin Hcl Brand 103 $1,734
Valacyclovir Valacyclovir Hcl Brand 11 $326
Latanoprost Generic 25 $245
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 11 $149
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 13 $122

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$188,869

Medicare's payments for the services billed

Medicare patients

308

Average age 74

Services billed

1,275

178 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 42%
Ischemic heart disease 28%
Diabetes 23%
Atrial fibrillation 18%
Depression 15%
Chronic kidney disease 14%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
$70,831 — —
MIEBO
$7,313 18 —
XIIDRA
$7,213 — —
VEVYE
$1,812 — —
Izervay
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

622 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record